Venus Remedies' novel drug for 'superbug' granted US patent
03 Aug 2011
Venus Remedies has received its first patent from the US Patent Office for its novel research product, `Vancoplus', which is used in the treatment of diseases caused by multi-drug resistant microbes, known as methicillin resistant staphylococcus aureus (MRSA), popularly called `superbug'.
Vancoplus, a brand of ceftriaxone and vancomycin used in chemical vector mediated compatibility (CVMC) technology, is the only remedy after vaccination to treat MRSA like meningitis, pneumonia, typhoid, septicemia, urinary tract infection, skin and skin infections and staphylococcal endocarditis, the company said in a release.
The drug restricts the production of toxin by MRSA pathogens and also reduces the treatment time, cost and adverse effects, Venus said in a filing with the Bombay Stock Exchange (BSE).
The patent is valid up to December 2027, the release said.
With the patent in hand, Venus said it is all set to tap the US market by launching the product. The company has already received patents from countries like South Africa, New Zealand and Ukraine for `Vancoplus'.
Vancoplus has been developed under stringent international standards for developing a new drug. The product has undergone various pre-clinical studies, which includes acute toxicity, sub-acute toxicity, intravenous, paravenous toxicities as per OECD guidelines besides pharmacokinetic studies and efficacy studies established through a series of microbiological studies carried out as per NCCLS guidelines, Venus said.
